Comparison between 80 kV, 100 kV and 120 kV CT protocols in the assessment of the therapeutic outcome in HCC

Citation for published version:
Quaia, E 2016, 'Comparison between 80 kV, 100 kV and 120 kV CT protocols in the assessment of the therapeutic outcome in HCC' Liver and Pancreatic Sciences, vol. 1, no. 1.

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Liver and Pancreatic Sciences

Publisher Rights Statement:
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Comparison between 80 kV, 100 kV and 120 kV CT protocols in the assessment of the therapeutic outcome in HCC

Emilio Quaia*
Department of Medical, Surgical and Health Sciences, Operative Unit of Radiology, Cattinara Hospital, Italy

Abstract

Aim: To compare the signal-to-noise ratio (SNR) and effective dose at low dose (80-100 kV) contrast-enhanced computed tomography (CT) to conventional contrast-enhanced CT (120 kV) in the assessment of the therapeutic outcome in patients with hepatocellular carcinoma (HCC) treated by thermal ablation and/or trans-arterial chemo-embolization (TACE).

Materials and methods: Twenty-one cirrhotic patients (15 male and 6 female, 71 years ± 15) with HCC(s) were referred to contrast-enhanced CT to assess therapeutic outcome after thermal ablation (n=7) or TACE (n=7) or thermal ablation and TACE (n=7). CT examination was performed at 120 kV after 370 mgI/mL contrast injection (120 kV-370 mgI/mL) before treatment, 100 kV after 370 mgI/mL contrast injection (100 kV-370 mgI/mL) at 3 months and 100 kV after 400 mgI/mL contrast injection (100 kV-400 mgI/mL) 6 months after treatment, and 80 kV after 400 mgI/mL contrast injection (100 kV-400 mgI/mL) at 12, 18 and 24 months after treatment. The SNR was calculated by drawing a region-of-interest in hepatic parenchyma and abdominal fat.

Results: 120 kV-370 mgI/mL vs. 100 kV-370 mgI/mL vs. 100 kV-400 mgI/mL vs. 80 kV-400 mgI/mL did not differ in SNR (3.4 ± 1.2 vs. 2.9 ± 1.16 vs. 2.9 ± 0.5 vs. 2.2 ± 1; ANOVA test, P=0.41) while differed in effective dose (27.9 ± 8.1 vs. 17.2 ± 4.6 vs. 19.2 ± 5.2 vs. 14 ± 5.8 mSv; ANOVA test, P=0.002).

Conclusion: Contrast-enhanced CT at 80-100 kV after high concentration iodinated contrast media injection does not reduce SNR but provides a significant reduction in the effective dose in cirrhotic patients undergoing follow-up after thermal ablation and/or TACE.

Introduction

The assessment and monitoring of therapeutic outcome after loco-regional treatment of hepatocellular carcinoma (HCC) in cirrhotic patients represents an essential item. According to the American Association for the Study of Liver Disease (ASL) [1] and the European Association for the study of the liver (EASL) [2] the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria [3,4] should be used to assess the therapeutic outcome in HCC treated by thermal ablation or trans-arterial chemo-embolization (TACE). mRECIST criteria are based on the measurement of the largest dimension of the enhancing tumoral tissue on arterial phase of dynamic computed tomography (CT) or magnetic resonance (MR) imaging [5–7].

Even though both CT and MR imaging are accepted as the imaging modalities to be used in the assessment of the therapeutic outcome in HCC according to the mRECIST criteria [3,4], CT is still the most employed imaging technique in the clinical practice. On the other hand the radiation exposure during CT studies is of concern, especially in patients with HCC who need a prolonged imaging follow-up for an accurate assessment of the therapeutic outcome after loco-regional treatments including thermal ablation and TACE [3,4]. In these patients, due to multiple CT examinations scheduled during the imaging follow-up period, radiation dose should be kept at a minimum level provided that a diagnostically adequate image quality is maintained. Since the attenuation effect of iodinated contrast material is greater at the mean x-ray photon energy closer to the k-edge of iodine (33.2 KeV), low tube voltage (80 kVp) compared with high tube voltage acquisition (120 kVp) determines that an higher number of x-ray photons on the lower end of the energy spectrum presents a photoelectric interaction with the K-shell electrons with a consequent higher attenuation. For these reasons the use of a low tube voltage allows to employ a lower amount of iodinated contrast material required to achieve the same degree of contrast enhancement [8] and without image quality degradation [9].

By decreasing the tube voltage, the amount of iodinated contrast material can be reduced. In particular, the minimal iodine (I) dose required to achieve an acceptable tumor-to-liver contrast-to-noise ratio on 80-kVp corresponds to 0.3 g I/kg or 11 g I/m² [10], while for CT performed at 120 kVp the iodine dose necessary to achieve 50-HU hepatic enhancement on portal venous phase is 0.521 g I/kg or 18.6 g I/m² [11–14].

The aim of the present study was to compare 80 kV, 100 kV and 120 kV protocols in the assessment of the therapeutic outcome in HCC.

Correspondence to: Emilio Quaia, Associate Professor of Radiology, Department of Medical, Surgical and Health Sciences, Operative Unit of Radiology, Cattinara Hospital, Strada di Fiume 447, 34149, Trieste, Italy, E-mail: quaia@units.it

Key words: CT, liver, HCC, effective dose, signal-to-noise ratio

Received: October 08, 2016; Accepted: November 11, 2016; Published: November 15, 2016
Materials and methods

Patients

This was a prospective observational study which was approved by the IRB of our hospital with a waiver of patients’ informed consent.

Inclusion criteria were: patients with HCC diagnosis based on imaging criteria developed by EASL and ASL [1,2] or based on histology who were scheduled to undergo thermal ablation (radiofrequency or microwave) or TACE or thermal ablation and TACE at our institution; contrast-enhanced CT examination performed according the following four protocols employed according to the time from treatment: hepatic arterial phase -HAP- and late phase -LP- scan at 120 kV after 370 mgI/mL contrast media injection (Ultravist, Iopromide 370, Bayer, Berlin) before treatment (120 kV–370 mgI/mL); 100 kV after 370 mgI/ml contrast media injection (Ultravist, Iopromide 370, Bayer, Berlin) 3 months after treatment (100 kV–370 mgI/mL); 100 kV after 400 mgI/ml contrast media injection (Iomeron, Iomeprol 400, Bracco, Milan) 6 months after treatment (100 kV–400 mgI/mL); 80 kV after 400 mgI/ml contrast media injection (Iomeron, Iomeprol 400, Bracco, Milan) 12, 18 and 24 months after treatment (80 kV–400 mgI/mL); no more than 6 months between thermal ablation and TACE.

Initially, thirty-two patients were included over a period of three years. Eleven patients were excluded at the end of the study: in particular seven patients were not referred to the scheduled CT examinations during the follow-up, two patients did not undero HAP or LP acquisition at CT examination, and two patients had numerous HCCs involving the entire liver that may have changed hepatic hemodynamics.

Thus the final study sample consisted of 21 patients (15 male, 6 female; age range, 48–88 years; mean, 69 years ± 15; BMI, 20 - 25; mean, 55.0 ± 8.4 [SD], kg). The age range of the men was 48–88 years (mean, 67.5 years), and that of the women was 52–85 years (mean, 71.0 years).

Thermal ablation and tace

Strategies of HCC treatment by using thermal ablation and/or TACE were discussed at weekly multidisciplinary meetings and were based on pre-procedural CT images.

All thermal ablation procedures were performed by two radiologists with 8 and 10 years of experience in thermal ablation before starting our study. Treatments were performed with the use of local anesthesia and conscious analgesic sedation. Thermal ablation devices included commercially available internally cooled electrode systems for radiofrequency or microwave antenna with generators (HS AMICA - HS Hospital Service, Varese, Italy). Ablative margins of at least 0.5 cm beyond the tumor boundary were planned for all lesions, with the exception of sub-capsular and perivascular portions. After ablation, electrodes were retracted with cautereization of the electrode path to prevent or minimize bleeding or tumor seeding.

All TACE were performed after femoral artery cannulation with a 5-French catheter to outline the anatomy, delineate the tumors, and identify the portal vein. The third- or fourth-order branches of feeding vessels supplying the HCC were catheterized with a 2.8-French or a 2.1-French microcatheter. Then, the tumors were embolized with a slow fluoroscopy-guided injection of iodinated contrast material mixed with 100–300 µm low-compression beads impregnated with 50 mg of doxorubicin in each vial. The first- and second-order branches of the right or left hepatic arteries were kept patent and documented on postembolization completion angiography.

CT examination

CT of the liver was performed with 256-row multi-detector row CT system (Brilliance iCT 256, Philips, Best, The Netherlands) before and 3, 6, 12, 18 and 24 months after treatment. In those patients who underwent to a second treatment by thermal ablation or TACE, the contrast-enhanced CT follow-up examination was re-scheduled at 3, 6, 12, 18 and 24 months from the last loco-regional treatment. Each contrast-enhanced CT examination consisted in HAP scan (automatic bolus-tracking with a delay of 18 seconds after the threshold of 120 HU had been reached in the abdominal aorta) and LP scan (3 minutes from the beginning of contrast injection) after the i.v. bolus injection of iodinated contrast material (120 mL of iodinated contrast injected at 4 mL/sec followed by 50 mL of saline flush at 2 mL/sec) administered with a dual-syringe power injector (Stellant CT injector, Medrad, Indianola, PA) via a 20-gauge catheter inserted into an antecubital vein. Patients were instructed to hold their breath with tidal inspiration during scanning.

Technical parameters were: detector collimation; 0.625 mm; beam collimation, 128 × 2 × 0.625 mm; normalized beam pitch, 0.975; x-axis coverage, 32–160 mm; reconstruction interval, 0.3-mm; reconstructed section thickness, 3 mm; automatic exposure control on the basis of the x-ray attenuation on antero-posterior and lateral scout images and the reconstruction kernel; tube current (effective mA) 280–400 mA depending on patient size; x-ray tube rotation period, 0.4–0.27 s; field of view, 40 cm. Combined data from both x-ray tubes were reconstructed with weighted filtered back projection by using the B31f standard reconstruction kernel to generate standard-dose datasets (the standard reconstruction used at our institution).

Quantitative analysis

All quantitative analysis was performed on workstation Extended WorkSpace eXplore (Philips, Best, The Netherlands). One board-certified radiologist with 11 years of experience in liver CT and blinded to the different protocols measured the mean attenuation of the hepatic parenchyma with a circular region-of-interest (ROI) cursor.

Figure 1 shows the quantitative procedure used in the present study. Hepatic mean attenuation was measured in Hounsfield Units (HU) in three separate areas (left lobe – II segment - and anterior - V - and posterior - VII - segments of the right lobe) on images obtained at the level of the main portal vein on HAP. If one or more liver segments were absent due to previous resection the ROI was positioned on the posterior - VII - segments of the right lobe.
adjacent inferior or superior liver segment within the same liver lobe. The attenuation values for each liver segment were averaged and one single ROI value resulted from each exam. An attempt was made to maintain a constant ROI area of approximately 2 cm²; the range was 0.8–2.0 cm². Visible blood vessels, bile ducts, parenchyma areas treated by ablation or TACE, and artifacts were carefully excluded from ROI measurements in the hepatic parenchyma. One ROI was drawn in peritoneal abdominal fat adjacent to the liver, avoiding possible strands, and the standard deviation was recorded for the calculation of the signal-to-noise ratio (SNR) as: \( \text{SNR} = \frac{\text{Liver Mean HU}}{\text{SD}} \) where SD means standard deviation.

Contrast-to-noise ratio (CNR) was calculated using background attenuation values and noise from the abdominal fat at each arterial level as: \( \text{CNR} = \frac{\text{HU}_{\text{tumor}} - \text{HU}_{\text{tumor}}}{\text{SD}} \).

Attenuation measurements were obtained at hepatic parenchyma and within arterial ROIs as average HU and noise (standard deviation in HU within an ROI) at the level of the aorta at the takeoff of the superior mesenteric artery. The size of the ROIs was consistent for all subjects (52.9 mm² within the aorta). Reference data were obtained from ROIs in the surrounding musculature, either erector spinæ muscles or gluteal muscles.

**Qualitative analysis**

To compare image quality in the different protocols, two board-certified radiologists with 22 and 11 years of experience in abdominal CT performed consensual visual assessments of image quality including the visual assessment of noise and beam hardening artifacts in one single reading session. They were blinded to clinical data and evaluated both HAP and LP images. After their independent evaluations, the reviewers assigned a score in consensus. Image noise was quantified both HAP and LP and calculated the dose-length product (DLP, mGy x cm) for the whole length of the liver on the basis of the CTDIvol (mGy) and scan range (cm). We then estimated the effective radiation dose by using the following equation: Effective dose (mSv) = (CTDIvol × scan range) × 0.015 [15].

**Statistical analysis**

Statistical analysis was performed using MedCalc (Mariakerke, Belgium). A per-patient analysis was performed.

For data analysis, the SNR and effective dose values measured at CT examinations performed at 12, 18 and 24 months after treatment (80kV-400 mgI/ml) were averaged in each patient.

One-way ANOVA with Scheffè correction was employed to determine the differences in the SNR and DLP and effective dose among the different CT examination protocols (120 kV – 370 mgI/mL; 100 kV – 370 mgI/mL; 100 kV – 400 mgI/mL; 80 kV – 400 mgI/mL). For all statistical tests, a P value <0.05 was considered to indicate a statistically significant difference.

**Results**

Patients underwent only radiofrequency (n=2) or microwave (n=5) thermal ablation or only TACE (n=7) or thermal ablation and TACE (n=7). In those patients who underwent both thermal ablation and TACE the mean temporal range between the two procedures was mean ± SD, 4.43 ± 1 months (range 2 – 6 months).

The number of treated HCC nodules per patient were ≤2 (diameter ± SD, 24.23 mm ± 9.6; range 10–40 mm) treated by thermal ablation, 2 – 10 (diameter ± SD, 30.6 mm ± 17.1; range 10–80 mm) treated by TACE, and 1–3 (diameter ± SD, 24.9 mm ± 12.7; range 8–70mm) treated by thermal ablation and TACE.

On qualitative assessment CT images were quoted with a mean 2.5 visual score (range 2–3) without any significant difference (P=0.8) between the different technical protocols. Beam hardening artifacts were visualized only in the 80 kV protocol in all patients with a mean score = 2.

Table 1 shows the results of the SNR, CNR, DLP (mgI*cm), and the values of effective dose (mSv) for the different CT protocols. Within matched comparisons by Scheffe correction the protocols 120 kV - 370 mgI/mL vs. 100 kV - 370 mgI/mL vs. 100 kV - 400 mgI/mL vs. 80 kV - 400 mgI/mL did not differ in SNR (P=0.41).

The CNR was significantly different (P=0.03) within matched comparisons between the CT protocols 120 kV - 370 mgI/mL vs. 100 kV - 370 mgI/mL vs. 100 kV - 400 mgI/mL vs. 80 kV - 400 mgI/mL. On the other hand, no significant difference was found between 120 kV - 370 mgI/mL and 100 kV - 370 mgI/mL CT protocols (P=0.4).

The mean effective dose was significantly different (P=0.03) within

**Table 1. Signal - to - noise ratio for the different CT examination protocols.**

<table>
<thead>
<tr>
<th>Protocol</th>
<th>120 kV – 370 mgI/mL</th>
<th>100 kV – 370 mgI/mL</th>
<th>100 kV – 400 mgI/mL</th>
<th>80 kV – 400 mgI/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signal-to-noise ratio (SNR)</td>
<td>3.4 ± 1.2</td>
<td>1.9 ± 1.1</td>
<td>1.9 ± 0.5</td>
<td>2.2 ± 1</td>
</tr>
<tr>
<td>Contrast-to-noise ratio (CNR)</td>
<td>1.9 ± 4.12</td>
<td>0.42 ± 1.93</td>
<td>0.42 ± 1.9</td>
<td>0.2 ± 2.78</td>
</tr>
<tr>
<td>Dose - length product (mgI/cm²)</td>
<td>1861 ± 543.4</td>
<td>1148.7 ± 309.4</td>
<td>1232.3 ± 353.2</td>
<td>936.5 ± 389.7</td>
</tr>
<tr>
<td>Effective radiation dose (mSv)</td>
<td>27.9 ± 8.1</td>
<td>17.2 ± 4.6</td>
<td>19.2 ± 5.2</td>
<td>14 ± 5.8</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± standard deviation.
matched comparisons between the CT protocols 120 kV - 370 mgI/mL vs. 100 kV – 370 mgI/mL vs. 100 kV - 400 mgI/mL vs. 80 kV - 400 mgI/mL. On the other hand, no significant difference was found between 120 kV - 370 mgI/mL and 100 kV - 370 mgI/mL CT protocols (P=0.4).

**Discussion**

Currently contrast-enhanced CT is the most frequently used imaging modality to plan and to evaluate the therapeutic outcome in cirrhotic patients with HCC treated by thermal ablation or TACE. According to both EASL and ASL [1,2] patients treated by thermal ablation and TACE should undergo contrast-enhanced CT examination every 3-6 months to assess the therapeutic outcome. According to the mRECIST criteria [3,4] contrast - enhanced MR imaging has also been assessed as a valuable method to study patients with HCC, due to its inherent superior tissue contrast resolution and sensitivity for detection of both the lesion and associated posttreatment changes in particular after TACE. Anyway, lower costs and higher availability make CT the most used imaging technique for both HCC characterization and post-treatment follow-up for response assessment.

The principal finding of the present study was that CT examination at 80kV or 100kV after high concentration iodinated contrast agent (370 mgI/mL or 400 mgI/mL) injection is feasible in patients with HCC treated by loco-regional therapy by keeping the image quality at acceptable level and by minimizing the effective dose. In our study we found that low kV (80-100 kV) CT protocols after high concentration iodinated contrast media injection (370–400 mgI/mL) present a similar image quality and SNR and CNR but a lower effective dose than conventional CT protocol (120 kV). Beside cirrhotic patients with an HCC treated by loco-regional therapies, also those patients with a limited intra-venous access, patients who can receive a limited iodinated contrast dose due to renal failure, patients with subtle attenuation differences, young patients, and small and medium-sized adult patients could benefit from low kV CT examination.

The usual protocol for imaging cirrhotic patients with HCC who underwent loco-regional treatment consists in a multiple phase CT examination including unenhanced images (to allow characterization of residual haemorrhagic component), HAP based on a bolus-tracking method (for accurate peak arterial enhancement), portal venous phase at 60 or 70 seconds, and LP at 120 seconds after iodinated contrast injection at a rate of 4 to 5 mL/s. In this study we employed a biphasic contrast-enhanced CT protocol, excluding unenhanced and portal venous phase scan, to limit the effective dose in cirrhotic patients undergoing repeated CT examinations during the imaging follow-up with the assumption that the inclusion of only two phases, HAP and LP, would achieve comparable diagnostic performance to the conventional multiple phase protocol.

In keeping with our results, a recent study showed that the 80-kV CT protocol with the contrast media dose reduced by 50% (300 mgI/kg) yielded contrast enhancement equivalent to the conventional 120-kVp protocol with the standard contrast media dose (600 mgI/ml) [16]. In our study we maintained roughly the same iodine load per patient (370 mgI/mL for iodine 400 mgI/mL and 410 – 530 mgI/kg for iodine 370 mgI/mL) and the same fractional dose of iodinated contrast agent (21-22 mgI/kg/sec) by keeping constant the volume of iodinated agent administered for each patient.

According to our results in a patient population with a BMI in the range of 20 - 25, low-dose dual-phase CT at 80kV KVP or 100 kV after 370 mgI/mL or 400 mgI/mL contrast media injection allow to provide the maximal radiation dose reduction with a DLP mean value (<800 mGy*cm) within the diagnostic reference levels for the abdomen [17] and with acceptable SNR to monitor the therapeutic outcome in cirrhotic patients. Even though the noise level increases at low kV (80–100 kV) the SNR remains comparable to conventional 120kV CT scan. This was likely due to the higher photon attenuation from photoelectric interaction with the K-shell electrons and the higher iodine concentration contrast agent (370–400 mgI/mL) used at 80–100 kV in the present study. Our results are also in keeping with previous studies in which low-kV CT scan provided SNR and CNR values comparable to 120-kV CT scan [18–20]. Consequently, we believe that low-kV CT (80-100 kV) could be employed routinely in patients with HCC during the imaging follow-up after loco-regional treatment.

Our study is limited by its observational nature and the reduced patients’ number due to the strict inclusion criteria. In conclusion, contrast-enhanced CT at 80-100 kV does not reduce SNR but provides effective dose reduction in cirrhotic patients undergoing follow-up after thermal ablation and/or TACE.

**References**


Copyright: ©2016 Quaia E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.